Anti-CD80 [16C10]

Absolute Antibody

Anti-CD80 [16C10]

9

This antibody binds human CD80 and inhibits the B7.1:CD28 pathway.

This antibody can be used for identification of human B7.1 antigen and is capable of inhibiting the binding of B7.1 to CD28, however it does not block the binding of B7.1 to CTLA-4. This antibody further inhibits the production of IL-2. Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. The binding of the antibody to soluble B7.1 was tested using ELISA. This antibody tested positive for binding to human C1q protein. This antibody is reported to cause keratinocyte hyperproliferation and decrease in psoriasis by inhibiting the B7:CD28 pathway. This antibody is further reported to be useful for the treatment of intestinal inflammation and rheumatoid arthritis.

ELISA, Neutralisation/Blocking

Research Use Only

Monoclonal

16C10

CD80

CD80 molecule

activation B7-1 antigen; B7; B7.1; B7-1; BB1; B-lymphocyte activation antigen B7; CD28LG; CD28LG1; CD80 antigen (CD28 antigen ligand 1, B7-1 antigen); costimulatory factor CD80; costimulatory molecule variant IgV-CD80; CTLA-4 counter-receptor B7.1; LAB7; T-lymphocyte activation antigen CD80

Human

IgG1

T-lymphocyte activation antigen CD80

This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Human

-20°C,2°C to 8°C

12352203